Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing

被引:0
作者
Kai Chen
Qi Wang
Xinxin Liu
Xiaodong Tian
Aimei Dong
Yinmo Yang
机构
[1] Peking University First Hospital,Department of General Surgery
[2] Peking University First Hospital,Department of Endocrinology
来源
Journal of Translational Medicine | / 21卷
关键词
Immune profiles; Pancreatic cancer; scRNA-seq; Prognosis; Quantitative pathology;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 90 条
[1]  
Siegel RL(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
[2]  
Miller KD(2021)Pancreatic cancer: a review JAMA 326 851-862
[3]  
Fuchs HE(2021)Updates on the management of pancreatic cancer Surg Oncol Clin N Am 393 1819-1830
[4]  
Jemal A(2019)Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Lancet 369 134-144
[5]  
Park W(2013)Safety and tumor responses with lambrolizumab (anti-PD1) in melanoma N Engl J Med 363 711-723
[6]  
Chawla A(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 383 2207-2218
[7]  
O'Reilly EM(2020)Pembrolizumab in microsatellite-instability-high advanced colorectal cancer N Engl J Med 18 1182-1191
[8]  
Tsai S(2017)Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Lancet Oncol 40 135-153
[9]  
Evans DB(2020)Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy Cancer Commun 38 1074-1084
[10]  
Mok TSK(2017)Comparative analysis of single-cell RNA sequencing methods Mol Cell. 14 847-856